Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients

Melek Simsek, Berrie Meijer, Dewkoemar Ramsoekh, Gerd Bouma, Egbert-Jan van der Wouden, Bert den Hartog, Annemarie C. de Vries, Frank Hoentjen, Gerard Dijkstra, Sybrand Y. de Boer, Jeroen M. Jansen, Andrea E. van der Meulen, Ruud Beukers, Menno A. Brink, Toos Steinhauser, Bas Oldenburg, Lennard P. Gilissen, Ton H. Naber, Marc A. Verhagen, Nanne K. H. de BoerChris J. J. Mulder, Dutch Initiative on Crohn and Colitis (ICC)

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD).1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown.2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.

Original languageEnglish
Pages (from-to)568-570
Number of pages3
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number3
Early online date2018
DOIs
Publication statusPublished - 1 Feb 2019

Cite this